Viewing Study NCT04858334

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2026-06-14 @ 8:45 AM
Study NCT ID: NCT04858334
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2021-04-23
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Pancreatic Acinar Cell Carcinoma View
None Pancreatic Adenosquamous Carcinoma View
None Pancreatic Squamous Cell Carcinoma View
None Resectable Pancreatic Acinar Cell Carcinoma View
None Resectable Pancreatic Adenocarcinoma View
None Resectable Pancreatic Adenosquamous Carcinoma View
None Resectable Pancreatic Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Adjuvant View
None Resected Pancreatic cancer View
None Pancreatic adenocarcinoma View
None BRCA1 View
None BRCA2 View
None BRCA1 mutation View
None BRCA2 mutation View
None PALB2 PALB2 mutation View
None PARP inhibitor View
None PARP View
None Olaparib View